



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Paul O.P. Ts'o et al. Art Unit : 1623  
Serial No. : 09/998,497 Examiner : H. Owens  
Filed : November 30, 2001  
Title : CONJUGATES OF GLYCOSYLATED/GALACTOSYLED PEPTIDE,  
BIFUNCTIONAL LINKER AND NUCLEOTIDIC MONOMERS/POLYMERS,  
AND RELATED COMPOSITION AND METHODS OF USE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of §1.17(p) is enclosed. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

  
Anita L. Meiklejohn, Ph.D.  
Reg. No. 35,283

Date: 23 March 2004

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20825229.doc

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL


I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 23, 2004  
Date of Deposit  
Carrie A. Amonte  
Signature  
Carrie A. Amonte  
Typed or Printed Name of Person Signing Certificate

03/26/2004 MBELETE1 00000002 09998497

01 FC:1806

180.00 OP


 Substitute Form PTO-1449  
 (Modified)

 U.S. Department of Commerce  
 Patent and Trademark Office

 Attorney's Docket No.  
 17223-002001

 Application No.  
 09/998,497

**Information Disclosure Statement  
by Applicant**  
 (Use several sheets if necessary)

(37 CFR §1.98(b))

 Applicant  
 Paul O.P. Ts'o et al.

 Filing Date  
 November 30, 2001

 Group Art Unit  
 1623

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,457,187	10/10/1995	Gmeiner et al.	536	25.5	
	AB	5,614,505	3/25/1997	Gmeiner et al.	514	50	
	AC	5,663,321	9/2/1997	Gmeiner et al.	536	25.5	
	AD	5,741,900	4/21/1998	Gmeiner et al.	536	25.31	
	AE	6,342,485	1/29/2002	Gmeiner et al.	514	44	

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AF							
	AG							
	AH							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AI	Desmoulin et al., "Metabolism of a novel nucleoside analogue, OGT 719, in the isolated perfused rat liver model, in rats..." Xenobiotica 33(3):289-303, 2003.
	AJ	Di Stefano et al., "Conjugation of 5-fluoro-2'-deoxyuridine with lactosaminated poly-l-lysine to reduce extrahepatic toxicity..." Ital. J. of Gastroenterol Hepatol. 30:173-177, 1998.
	AK	Rohlff et al., "Hepatocyte-activated glycol-conjugated 5-FU prodrug inhibits liver colonies of rat sarcoma" Pharmacology/Therapeutics: Proc. of the American Assoc. for Cancer Res. (abstract) 38:10, 1997.
	AL	Schwartz et al., "Characterization of the Asialoglycoprotein Receptor in a Continuous Hepatoma Line" J. of Biol. Chem. 256(17):8878-8881, 1981.
	AM	Schwartz et al., "Kinetics of Internalization and Recycling of the Asialoglycoprotein Receptor in a Hepatoma Cell Line" J. of Biol. Chem. 257(8):4230-4237, 1982.
	AN	Sharma et al., " Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver" Cancer Chemother. Pharmacol. 48:197-201, 2001.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.